Equibles does not estimate personal net worth.
Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRMY alertsHarmony Biosciences Holdings, Inc. reported in an 8-K filed March 24, 2025 that Adam Zaeske was appointed Executive Vice President and Chief Commercial Officer, effective March 31, 2025. Adam Zaeske has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Harmony Biosciences Holdings, Inc. on November 4, 2026. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey Dayno (CEO), Jeffrey M. Dayno (CEO and Board Member), Peter Anastasiou (CEO, COO and Board Member) and 7 others.
“On March 20, 2025, the Company named Adam Zaeske as the Company’s Executive Vice President and Chief Commercial Officer, effective March 31, 2025.”
“We continue to see extremely strong demand-driven growth for Wacix this quarter. Wacix achieved estimated average patients of 9,350, an increase of 400 patients in the quarter.”
“We're off to a strong start in the first quarter, with Wacix delivering $215.4 million in net sales, representing 17% year-over-year growth, now in its seventh year on the market, which is in line with the growth required to achieve full-year guidance of between $1 and $1.04 billion.”
“As you can tell from Jeff's comments, it's exciting times at Harmony, and especially with the performance of Wakex. We're really pleased with the momentum we're seeing as we finished 2025.”
“2025 marked a year of unprecedented and record-setting performance for Wacix, and that performance continued in the fourth quarter.”
“Harmony's Q3 2025 results were the strongest we've seen since launch. WAKIX delivered $239.5 million in net sales for the quarter, representing nearly 30% year-over-year growth in its sixth year on the market.”
Proxy statement
Start not stated–present
Last confirmed April 4, 2025
Biotechnology · Healthcare
